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Introduction
Alzheimer’s disease (AD), which is the most frequent cause of dementia among elderly peo-
ple, is a progressive neurodegenerative disorder manifested by cognitive and memory deterio-
ration, a variety of neuropsychiatric symptoms and behavioral disturbances, and progressive 
impairment of activities of daily living. There are currently no curative treatments that can re-
verse the disease progression of AD, so early diagnosis and slowing down the disease progres-
sion with some effective drugs is the best way to treat AD patients.
1 Neurofibrillary tangles 
and neuritic amyloid plaques represent the core neuropathologic features of AD. The precise 
factors responsible for the development of these lesions remain enigmatic, but the invariant 
consequence is the death of neurons. Neuronal death is the result of the process termed apop-
tosis, a complex cascade of intracellular events.
2,3 It has been suggested that peripheral cells, 
such as fibroblasts or cells in body fluids, can provide biological markers for research into 
the pathophysiology of AD.
4
During the process of immortalizing peripheral lymphocytes in our genome research into 
AD, we incidentally observed that lymphocytes from patients with AD showed poor prolifer-
ative activity, compared with normal controls. The lymphocytes of AD patients showed sh-
rinking and reduced viability, which decreased rapidly 3-4 weeks after their immortalization 
by the Epstein Barr virus. Previous study results from other investigators already demonstrat-
ed that the neuronal apoptotic mechanism may be involved in pathophysiology of AD.
2,3 Ba-
sed on our fortuitous observations, we have examined the hypothesis that the apoptotic patho-
physiology in AD patients is reflected in peripheral nucleated cells (lymphocytes) in the form 
of alterations in the cell viability and proliferation activity. We compared the cell viability and 
ObjectiveaaWe evaluated cell viability and proliferation activity of peripheral lymphocyt-
es as potential models of neuronal death in Alzheimer’s disease (AD). 
MethodsaaWe analyzed the cell viability and proliferation activity of phytohemagglutinin 
(PHA)-activated lymphocytes from 68 AD patients and 33 normal controls. The cellular meas-
ures were made at baseline (0 hr), 24 hrs, 48 hrs, 72 hrs, and 96 hrs after PHA stimulation. 
ResultsaaCell viability in the AD patients was significantly decreased at 72 hrs and 96 hrs, 
compared with the normal controls. The declining ramp of the proliferation activity from 48 
hrs to 72 hrs after PHA stimulation was significantly related to cell viability at 72 hrs and at 
96 hrs in the AD patients.
ConclusionaaLymphocytes from patients with AD have altered viability and proliferation 
characteristics in culture following PHA stimulation. These findings suggest that lymphocytes 
may be used as a peripheral tissue model of cell cycle dysregulation in AD.
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proliferation activity of peripheral lymphocytes following mi-
togenic stimulation in AD patients and normal controls. 
Methods
Subjects
Patients were recruited from the Clinical Trials Programs of 
the Samsung Medical Center Geropsychiatry Clinic. Details 
of the diagnostic procedure, and inclusion and exclusion cri-
teria are provided in a previous publication.
5 All patients re-
ceived a comprehensive neuropsychological screening bat-
tery, which cannot be detailed in this report. Severity of de-
mentia was assessed with the Korean version of the Mini-
Mental State Examination (K-MMSE),6 Seoul-Instrumental 
Activity of Daily Living (S-IADL),7 and the Clinical Demen-
tia Rating (CDR) scale.
8 In our Geropsychiatry Clinic, the in-
ter-observer diagnostic reliability of AD and non-AD demen-
tias is 90.3%. Brain magnetic resonance imaging and elec-
troencephalography were performed in all cases to exclude oth-
er possible causes of dementia. Patients with other neurologic 
or psychiatric disorders or clinically significant medical condi-
tions were excluded. No patient had a history of head trauma, 
or alcohol or drug abuse. Healthy volunteers with no history of 
memory impairment or psychiatric illness were recruited as 
normal controls by advertisement, and were matched to the pa-
tient group by age, sex and educational status. They were sc-
reened by the K-MMSE (K-MMSE score 27 or higher) and 
Minnesota Multiphasic Personality Inventory (on which they 
had validity and clinical scale scores ranging from 35 to 65). 
The protocol was approved by the ethics review board of Sam-
sung Medical Center, Seoul, Korea. Signed informed consent 
was obtained from all participants. Data from five subjects 
(four from AD patients and one from normal control) were ex-
cluded from analysis because of insufficient amount of speci-
men. In the final sample, 68 AD patients and 33 normal con-
trols were included for data analyses.
Measurement of the viability and proliferation
activity of lymphocytes
Venous blood was drawn between 0800 h and 1000 h for 
the separation of peripheral lymphocytes. The blood samples 
were heparinized, stored at 4°C immediately after venipunc-
ture, and assayed within 24 hrs. Blood mononuclear cells were 
isolated by centrifugation at 300 g for 15 min using the Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden) density gra-
dient technique. The cells were washed two times with phos-
phate buffered saline (PBS), and then the lymphocytes were 
separated with Hank’s Balanced Salt Solution. The lympho-
cytes obtained from patients and controls were cultured 
spontaneously in RPMI1640 (GIBCO) containing 10% fetal 
bovine serum (FBS) at 37°C with 5% CO2 after adding 20 μg/
mL of phytohemagglutinin (PHA, GIBCO), then measured 
as indicated below for the assessment of the viability and 
proliferation activity at various time points, viz. baseline (0 
hrs), 24 hrs, 48 hrs, 72 hrs and 96 hrs.
Quantitative determination of cell viability was performed 
using the live/dead assay by the trypan blue method. The 0.4% 
trypan blue solution (SIGMA) was added to the PHA-acti-
vated cells at different time points and then incubated at room 
temperature for 10 min. The blue-stained cells and non-stained 
cells were counted twice by means of a hemocytometer (live 
cells, not stained). Cell viability was calculated as percentage 
of viable cells to total cell number. The proliferation activity 
of the cells was determined by measuring the BrdU prolifera-
tion activity (Cell Proliferation ELISA, BrdU colorimetric kit, 
Roche, Mannheim, Germany). The PHA-activated cells at 
different time points were incubated at 37°C for 2 hrs, after 
adding 10 μL/well of BrdU labeling solution. The superna-
tants were separated by centrifugation at 300 g for 10 min. 
The pellets were dried at 60°C for 1 hr, incubated at room tem-
perature for 30 min after adding FixDenat solution 200 μL/
well, and then washed. 100 μL/well of Anti-BrdU POD 
working solution was added, and the wells were incubated at 
room temperature for 90 min, then washed three times to 
separate the conjugate antibody. 100 μL/well of TMB sub-
strate was added for the fluorescent reaction, and the wells in-
cubated at room temperature for 30 min. The reaction was 
stopped by adding 25 μL of 1M H2SO4. The fluorescence in-
tensity was measured by means of an ELISA reader at 450 
nm (reference wavelength 690 nm). 
Statistical analysis
The independent two-sample t-test and Mann-Whitney test 
were used to evaluate the difference in the cell viability/proli-
feration activity of the peripheral lymphocytes of the patients 
and controls at each time point. Non-parametric methods were 
applied to the statistical analyses of the variables, which were 
not normally distributed. The correlation between the cell via-
bility and proliferation activity of the lymphocytes in AD pa-
tient group was examined using Spearman’s correlation analy-
sis with Bonferroni’s correction. Relationships between the cell 
viability/proliferation activity of the lymphocytes and K-
MMSE, S-IADL and CDR scores in AD patient group were te-
sted using Spearman’s correlation analysis with Bonferroni’s 
correction. 
Results
Subject groups were of similar age (AD 72.1±9.5 years, 
control 71.3±5.2 years, p=0.29), female/male ratio (AD 49/19, 
control 22/11, p=0.58) and educational status (AD 8.4±5.1 
years, control 8.3±4.4, p=0.93). The AD group had mild to 
severe dementia with a mean K-MMSE score of 14.6±7.3 (ran-
ge 1, 26) and a mean CDR score of 1.51±0.85 (range 1, 3) by 70  Psychiatry Investig 2010;7:68-71
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CDR. The microscopic comparison of the viability of the pe-
ripheral lymphocytes from the patient with AD and normal 
controls, cultured for 96 hours in RPMI1640 after adding 
PHA, is illustrated in Figure 1. The lymphocytes from the pa-
tients with AD had different viability characteristics than con-
trol lymphocytes after stimulation with PHA. 
During the early phase of lymphocyte culture, we did not 
observe any difference of cell viability between the two gro-
ups. The cell viability at 24 hrs (91.5±5.8% vs. 91.2±5.4%, 
p=1.0000) and 48 hrs (89.8±6.1% vs. 91.4±4.4%, p=1.0000) 
after PHA stimulation showed no difference between the AD 
and control group. However, at later time points, the cell via-
bility of the lymphocytes from the AD group decreased more 
rapidly and showed a significant reduction at 72 hrs (78.9±8.9% 
vs. 85.4±7.8%, p=0.002) and 96 hrs (70.7±12.1% vs. 83.3± 
9.8%, p=0.0004) after PHA stimulation, compared to the con-
trol group (Figure 2A). The proliferation activity detected in 
the AD group did not differ significantly from that in the con-
trol group at any time point. In AD group, the proliferation ac-
tivity tended to be higher than that in the control group at 24 
hrs (median, interquartile interval ; 0.37, 0.17-0.56% vs. 0.23, 
0.13-0.35%, p=0.0796) and 48 hrs (0.50, 0.35-0.73% vs. 0.42, 
0.30-0.62%, p=0.1668), then showed a rapid decline by 96 hrs 
(declining ramp of proliferation from 72 hrs to 96 hrs; -0.08, 
-0.15 - -0.03%/hr vs. -0.01, -0.12 - 0.02%/hr, p=0.011)(Figure 
2B). The decline of the proliferation activity appeared to be 
earlier in the AD than that in the control group. The declining 
ramp of the proliferation activity from 48 hrs to 72 hrs after 
PHA stimulation was significantly correlated with cell viabil-
ity at 72 hrs (ρ=0.442, p<0.001) and at 96 hrs (ρ= 0.436, 
p<0.001) in AD patients. There was no correlation between 
the cell viability/proliferation activity of lymphocytes and 
clinical scores reflecting severity of dementia (K-MMSE, S-
IADL, CDR) in the AD group (data not shown).
Discussion
We demonstrated that the peripheral lymphocytes from 
patients with AD had altered viability during culture stimulat-
ed with PHA, compared to those from controls. The cell via-
bility of lymphocytes in AD patients decreased more rapidly 
after mitogenic stimulation than in normal controls (Figures 
1 and 2).
The specific mechanisms responsible for this poor viability 
and premature death of lymphocytes in AD patients remain to 
be elucidated. Previous studies reported various biological dis-
turbances in lymphocytes of AD patients, including cell cycle 
dysregulation and alterations of the immune system.
9-11 A 
strong possibility is that the cell cycle dysregulation may be 
linked with this premature death of peripheral lymphocytes in 
AD. The relation between abnormal cell cycle regulation, neu-
ronal cell death and the pathogenesis of neurodegenerative 
diseases such as AD has been well documented.
12 Peripheral 
lymphocytes, as in the case of neurons in the adult brain, are 
paused in the quiescent phase of the cell cycle, in which they 
are differentiated but not proliferating. The reactivation of the 
cell cycle by mitogenic stimuli (PHA in our study) leads to cell 
proliferation. Nagy et al.
13 reported abnormal cell cycle kine-
A   B  
Figure 1. Comparison of the viability of 
peripheral lymphocytes from (A) pa-
tients with Alzheimer’s disease and (B) 
normal controls, cultured for 96 hours in 
RPMI1640 after adding phytohemagglu-
tinin. The bright yellow fluorescence in-
dicates live lymphocytes.
Figure 2. A: Cell viability of phytohemag-
glutinin-activated lymphocytes from pa-
tients with AD and NC. B: Proliferation 
activity of phytohemagglutinin-activated 
lymphocytes from patients with AD and 
NC. *p<0.05. SE: standard error, O.D: op-
tical densities, AD: Alzheimer’s disease, 
NC: normal controls.
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sis in the lymphocytes of AD patients based on the in vitro re-
sponsiveness to a G1 inhibitor (rapamycin). We observed that 
the declining ramp after gradual increase of the proliferation 
activity was significantly correlated with cell viability in the 
later phase. Our finding also supports the hypothesis that the 
cell cycle dysregulation in peripheral lymphocytes precedes 
subsequent cell death. In addition, an alteration of the immu-
ne system itself may contribute to the poor viability of lympho-
cytes in AD patients. A difference in the T cell subpopulations,
9 
a role by the immunity receptor such as CD14
10 and the decrea-
sed expression of an early proliferation marker of lymphocy-
tes
11 have been reported in AD patients. 
We did not find any relationship between the cell viability/
proliferation activity of lymphocytes and clinical scores re-
flecting disease severity in the AD group. However, this result 
is in agreement with those of previous studies regarding cell 
cycle dysregulation as a biomarker of an early event in AD.
11,12 
In view of this lack of correlation with disease severity, it is 
possible that the alterations of lymphocyte viability or prolife-
ration activity in AD patients may appear early, before the on-
set of clinical dementia symptoms. 
The cell viability and proliferation activity in the peripheral 
lymphocytes of AD patients were altered in patients with es-
tablished probable AD. These preliminary finding suggests 
that lymphocytes may be used as a peripheral tissue model to 
develop biomarker of AD.
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